Plasma Metabolomic Profiles in Different Stages of CKD
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Background and objectives: CKD is a common public health problem. Identifying biomarkers adds prognostic/diagnostic value by contributing to an understanding of CKD at the molecular level and possibly defining new drug targets. Metabolomics provides a snapshot of biochemical events at a particular time in the progression of CKD. This cross-sectional metabolomics study ascertained whether plasma metabolite profiles are significantly different in CKD stages 2, 3, and 4. Design, setting, participants, & measurements: An analysis of plasma metabolites, using gas and liquid chromatography coupled to mass spectrometry, was conducted on 30 nondiabetic men ages 40–52 years, with 10 participants each in CKD stages 2, 3, and 4 based on their estimated GFR (calculated by the Modified Diet in Renal Disease formula). Participants were recruited in late 2008, and plasma samples were tested at Metabolon Inc and analyzed in 2012. Results: Comparison of stage 3/stage 2 identified 62 metabolites that differed (P≤0.05), with 39 higher and 23 lower in stage 3 compared with stage 2; comparisons of stage 4/stage 2 identified 111 metabolites, with 66 higher and 45 lower; and comparisons of stage 4/stage 3 identified 11 metabolites, with 7 higher and 4 lower. Major differences in metabolite profiles with increasing stage of CKD were observed, including altered arginine metabolism, elevated coagulation/inflammation, impaired carboxylate anion transport, and decreased adrenal steroid hormone production. Conclusions: Global metabolite profiling of plasma uncovered potential biomarkers of stages of CKD. Moreover, these biomarkers provide insight into possible pathophysiologic processes that may contribute to progression of CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
The L-Arginine-Nitric Oxide Pathway
Epstein, F. H., Moncada, S., & Higgs, A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292706 · Cited by 6,678
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
Leone, A., Moncada, S., Vallance, P., Calver, A., & Collier, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)90865-z · Cited by 2,107
Ohta, T., Masutomi, N., Tsutsui, N., Sakairi, T., Mitchell, M., Milburn, M. V., Ryals, J. A., Beebe, K. D., & Guo, L. (2009) · Toxicologic Pathology · doi:10.1177/0192623309336152 · Cited by 213 · cited 1×
“Samples were processed essentially as described previously (12,13).”
Method
Cited by
Metabolomics for clinical use and research in chronic kidney disease
Hocher, B., & Adamski, J. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.30 · Cited by 339
A Combined Epidemiologic and Metabolomic Approach Improves CKD Prediction
Rhee, E. P., Clish, C. B., Ghorbani, A., Larson, M. G., Elmariah, S., McCabe, E., Yang, Q., Cheng, S., Pierce, K., Deik, A., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012101006 · Cited by 307
Inhibiting aerobic glycolysis suppresses renal interstitial fibroblast activation and renal fibrosis
Ding, H., Jiang, L., Xu, J., Bai, F., Zhou, Y., Yuan, Q., Luo, J., Zen, K., & Yang, J. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00036.2017 · Cited by 250
“Despite extensive efforts to identify the critical cellular and molecular mediators of renal fibrosis, the final common pathway of a wide variety of CKD (26), the mechanisms that govern renal fibrosis remain incompletely understood, and currently there is no effective clinical treatment to stop the progression of rena…”
BackgroundInfluentialBiomarkers in diabetic nephropathy: Present and future
Currie, G. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i6.763 · Cited by 182
An overview of renal metabolomics
Kalim, S., & Rhee, E. P. (2017) · Kidney International · doi:10.1016/j.kint.2016.08.021 · Cited by 173
Metadata
- Authors
- Shah, V. O., Townsend, R. R., Feldman, H. I., Pappan, K. L., Kensicki, E., & Vander Jagt, D. L.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2013-03
- Volume
- 8
- Issue
- 3
- Pages
- 363-370
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2097320597
- Cited by
- 113
- References
- 5
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma Metabolomic Profiles in Different Stages of CKD. https://app.cochat.ai/papers/10.2215/cjn.05540512
- The paper
- Shah, V. O., Townsend, R. R., Feldman, H. I., Pappan, K. L., Kensicki, E., & Vander Jagt, D. L. (2013). Plasma Metabolomic Profiles in Different Stages of CKD. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.05540512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.